Globally, around half of all patients with cancer require radiotherapy as a part of their multimodality cancer treatment.1 Despite its important role in optimising cancer outcomes, its systemic immunological consequences, particularly radiation-induced lymphocytopenia, can pose a significant challenge and be associated with poorer treatment outcomes that impact the overall survival.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by John Conibear
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot
randomized controlled trial respiratory tract tumours radiation oncology adult oncology Thoracic surgery Lung Diseases The study has a pragmatic design integrated into the standard care pathway at the majority of UK hospitals. A study for patients who present with extensive (poly-metastatic) disease that becomes oligometastatic (ie, induced oligometastatic) disease after initial systemic anti-cancer treatment.
The impact of COVID-19 on national targets in radical lung cancer radiotherapy: a single centre clinical audit
The impact of virtual lung MDT meetings (MDTMs) in response to the COVID-19 pandemic
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
Abstract When treating patients with unresectable stage III non-small-cell lung cancer (NSCLC), those with a good performance status and disease measured within a radical treatment volume should be considered for definitive concurrent chemoradiotherapy (cCRT). This guidance is based on key scientific rationale from two large Phase 3 randomised studies and meta-analyses demonstrating the superiority of cCRT over sequential (sCRT).
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer
The trial will undergo an early feasibility review after 50 randomised patients to ensure full recruitment is likely to be achievable. Patients requiring both conventional thoracic radiotherapy to the primary and stereotactic ablative radiotherapy (SABR) to a thoracic metastasis will be included in a thoracic SABR safety substudy to assess toxicity and planning issues in this unique and challenging subgroup of patients more thoroughly.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with John
Contact John, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack